PRP in ACLR to Prevent PTOA

Launched by HOSPITAL FOR SPECIAL SURGERY, NEW YORK · Jun 7, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a treatment called platelet-rich plasma (PRP) injections for patients who have recently injured their anterior cruciate ligament (ACL), a key ligament in the knee. The goal is to see if PRP can help reduce inflammation and improve joint function in the short term after an injury. This trial is currently recruiting participants aged 14 to 50 who have experienced an ACL injury within the last six weeks. Individuals with certain types of knee injuries will also be eligible, especially if they have a meniscus injury that can be treated.

Participants in the study can expect to receive a PRP injection and will be monitored for changes in their knee function and inflammation levels over time. It's important to note that individuals who have had previous knee surgeries, certain types of injections, or specific knee injuries may not be eligible to join the trial. This study is considered a pilot, meaning it is an initial exploration to gather information and will help researchers understand how PRP might be used in the future for ACL injuries.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Acute ACL injury within 6 weeks of presentation
• • Age 14-50
• • Male or female
• • Meniscus injury that can be treated with meniscectomy or repair (the lack of meniscus injury will not exclude patients)
• Exclusion Criteria:
• • Prior ACL reconstruction
• • Prior cartilage repair procedure
• • Prior meniscus surgery within 12 months
• • Prior steroid, hyaluronic acid, or PRP injection within 6 months
• • Other ligament injury requiring repair
• • Any cartilage lesion requiring repair
• • Any cartilage lesion greater than grade 2 (partial thickness injury)
• • History of inflammatory arthritis or joint sepsis
• • Non English speakers